{
    "clinical_study": {
        "@rank": "151388", 
        "arm_group": [
            {
                "arm_group_label": "Pravastatin", 
                "arm_group_type": "Experimental", 
                "description": "Single 40 milligram (mg) oral dose of pravastatin administered on Day 1."
            }, 
            {
                "arm_group_label": "Evacetrapib + Pravastatin", 
                "arm_group_type": "Experimental", 
                "description": "Oral doses of 130 mg evacetrapib administered once daily on Days 2-11, with a single oral dose of 40 mg pravastatin coadministered on Day 11"
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to look at the effect of evacetrapib on pravastatin levels\n      in the blood when both drugs are taken at the same time. The study will also assess how well\n      the body handles evacetrapib and pravastatin when given at the same time.\n\n      This study has two periods in fixed order.  Each participant will enroll in both periods.\n      This study will last approximately 25 days, not including screening."
        }, 
        "brief_title": "A Study of Evacetrapib in Japanese and Non-Japanese Participants", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Overtly healthy participants, as determined by medical history and physical\n             examination\n\n          -  Have a body mass index of 18 to 32 kilograms per square meter (kg/m^2)\n\n          -  Japanese participants must be 1st generation Japanese"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01958489", 
            "org_study_id": "14625", 
            "secondary_id": "I1V-MC-EIAW"
        }, 
        "intervention": [
            {
                "arm_group_label": "Evacetrapib + Pravastatin", 
                "description": "Administered orally", 
                "intervention_name": "Evacetrapib", 
                "intervention_type": "Drug", 
                "other_name": "LY2484595"
            }, 
            {
                "arm_group_label": [
                    "Pravastatin", 
                    "Evacetrapib + Pravastatin"
                ], 
                "description": "Administered orally", 
                "intervention_name": "Pravastatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Pravastatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leeds", 
                    "country": "United Kingdom", 
                    "state": "West Yorkshire", 
                    "zip": "LS2 9LH"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Evacetrapib on the Pharmacokinetics of Pravastatin in Healthy Japanese and Non-Japanese Subjects", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics: Maximum Concentration (Cmax) of Pravastatin", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 11: Predose through 24 hours postdose"
            }, 
            {
                "measure": "Pharmacokinetics: Area Under the Concentration Versus Time Curve from Zero to Infinity (AUC[0-\u221e]) of Pravastatin", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 11: Predose through 24 hours postdose"
            }, 
            {
                "measure": "Pharmacokinetics: Time of Maximum Observed Concentration (tmax) of Pravastatin", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 11: Predose through 24 hours postdose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01958489"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}